Ok, so your probably thinking what I have told you is all well and good but what would one of these decision support tools for a trial look like. To date.

Slides:



Advertisements
Similar presentations
National Cancer Survivorship Initiative Developing the NCSI 2012 document: taking action to improve outcomes.
Advertisements

Health Literacy: how to explain risk? Dr. Keiko Yasukawa University of Technology, Sydney.
Project IMPACT IMPACT National Medical Association What African Americans Should Know About Clinical Trials You’ve Got the Power!
CVD prevention & management: a new approach for primary care Rod Jackson School of Population Health University of Auckland New Zealand.
Extension Article by Dr Tim Kenny
Binary Decision Diagrams1 BINARY DECISION DIAGRAMS.
Cancer Program Standards 2012: Ensuring Patient-Centered Care
Epi Team Challenge Detectives in the Classroom - Investigation 2-7: Epi Team Challenge Epi Team Challenge.
Sample Size Determination
Cancer Clinical Trials: The Way We Make Progress Against Cancer.
Myths and Facts About Cancer Clinical Trials. Copyright ENACCT, 2007 It’s a treatment of “last resort!” They treat you like a “guinea pig ” No one benefits.
Research-driven data standards CIMI 11 th April 2013.
ACRIN 6657/CALGB Consent for Research Study Contrast-Enhanced Breast MRI and MRS: A Correlative Science Studies to Characterize Tumor Response in.
Rooms at NHOG, Suite 403, SAN Clinic, Wahroonga and appointments via Telehealth to rural and remote areas T:
Home More Information about I-SPY 2 Participating Cancer Centers Peer Support for I-SPY 2 Participants More Information About Breast Cancer I-SPY 2 Breast.
Balancing the Costs & Benefits In thinking about medical advances we must consider both sides of the equation Progress is important Controlling costs is.
Consent for Research Study A study using 18 F-Fluoride for prostate cancer patients currently enrolled in Dr. Febbo’s “Genomic Guided Therapy” study A.
Updated 7/2015 AGENDA Susan G. Komen ® Introduction Local Organization/Komen Affiliate information Breast cancer information –Breast cancer statistics.
Infinite Campus Gradebook Created by: Computer Education Support (Jefferson County Public Schools)
Title of the work subject to the challenge Author, affiliation Supervisor(s), affiliation Date of Beginning and predicted End.
Research Issues Can be both sociological and ethical Excesses in the past have made rules and standards necessary Rules are participant oriented and protective.
InformedConsent Q $100 Q $200 Q $300 Q $400 Q $500 Q $100 Q $200 Q $300 Q $400 Q $500 Final JeopardyJeopardy.
Breast cancer affects 1 in 8 women during their lives. 1 Population Statistics.
Slide presentation title to go here Secondary information to go here Date to go here.
Midterm/Final Presentation Project Name Students: [Name1], [Name2] Supervisor: [SV Name] Context: Project [A/B/Special] Semester: Winter/Spring, Year Date:
Clinical Trials The Way We Make Progress Against Disease.
Chapter 10 Lesson 10.2 Hypotheses and Test Procedures 10.2: Errors in Hypothesis Testing.
CS 307: Final Presentation Project Name Student One Student Two Student Three Student Four Purdue University, Date.
Discussing numerical data with patients. Framing Framing manipulations: describing equivalent choice situations in different ways Information on relative.
Infinite Campus Gradebook & Lesson Planner Created by: Tanya Fluke (Spencer County Public Schools)
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials The Lancet Volume 386, Issue.
Trainers name(s) here.
Patient Focused Drug Development An FDA Perspective
The Clinical Trial Volunteer’s Bill of Rights
Get ready for today… Yes, Cornell notes!
IAEA E-learning Program
Clinical Trials — A Closer Look
Optimal Ways to learn about and communicate Evidence Based Medicine
By: Jake Henderson, Meagan McMahan
Your Symptoms Matter – Prostate Cancer
Learning About PET/CT Scans:
Positive Impacts of Developing Novel Endpoints Generated by Mobile Technology for Use in Clinical Trials* SPECIFIC BENEFITS   SHORT-TERM MEDIUM-TERM LONG-TERM.
سرطان الثدي Breast Cancer
Samples of Teacher-Scribed Work Samples
**This may be expedited depending on PRMC SOP
Open enrollment is on the horizon Open enrollment is on the horizon
Open enrollment is on the horizon Open enrollment is on the horizon
Metabolically Healthy Patients With Obesity
Using CDK4/6 Inhibitors to Manage HR-Positive Metastatic Breast Cancer
A B C TOWER BLOCK TOOL KIT BLOCK TOWER TOOL KIT
Type I and Type II Error AP Stat February 28th 2011.
The Road to Quality Improvement in HER2-Positive Breast Cancer
Bell Ringer Open your student workbook to page 69.
Draw the balance scales shown below on a blank page after Page 105.
Diabetes Pandemic. The Economics of Managing Patients With Diabetes and Coronary Artery Disease: A Payer Perspective.
National Cancer Patient Experience Survey 2015
New Paradigms in HR-Positive Advanced Breast Cancer
The relative efficacy of topical non-steroidal anti-inflammatory drugs and capsaicin in osteoarthritis: a network meta-analysis of randomised controlled.
Masterclass on lifestyle change How to help patients lose weight?
Joanna Travis-Roberts Project Manager - ISSUP
Patient charts By: Doctor (YOUR NAME!!!).
Name Date Subject and Grade
Characteristics of Large Randomized Controlled Statin Trials Included in the Present Analysis Alawi A. et al. JACC 2008 Aug 20 [Epub ahead of print]
Graphing Inequalities
Slide presentation title Secondary information
Slide presentation title Secondary information
Maximizing Disease-Free Survival in Early-Stage HER2-Positive Breast Cancer.
NAFLD and NASH in Europe and Canada
Use of a Decision Aid for Patients Considering Peritoneal Dialysis and In-Center Hemodialysis: A Randomized Controlled Trial  Lalita Subramanian, Junhui.
How to complete a form A step-by-step guide ReSPECT (version 1.0)
Presentation transcript:

Ok, so your probably thinking what I have told you is all well and good but what would one of these decision support tools for a trial look like. To date there is only 1 developed – and it was developed by a group in Australia for a breast cancer treatment trial. I have copied a few of the pages in the next few slides to hopefully show that presenting information differently, and including information required for high quality decisions is possible in this context. So these first pages are really describing the risk of the incidence of the disease to the patient and setting out, in a pictoral form, what their decision is about.

These pages go on to look at potential benefits or side effects of taking the trial drug. Importantly the diagrams on the right with the dots, have been shown to be particularily useful for conveying risk information in a treatment context and so have also been applied here.

Lastly, this page lays out a summary of what is expected of the particpant, in terms of trial follow up, should they decide to participate whilst the other side provides an example of somebody else’s decision when considering particiaption, using a weighted scale to help them think through what matters most to them in the decision. The participant is then provided with a blank scale n which they can circle what values matter most to them – which helps them work through their decison.